Cardiology
Clinical application of antithrombotic therapy in both arterial disease (acute coronary syndromes, acute MI, peripheral arterial disease, valvular heart disease, atrial fibrillation) and venous disease, (venous thromboembolic disease and pulmonary embolism). Results of major clinical trials and their implications for clinical practice are reviewed.
Presents the rationale for why physicians should more aggressively treat hypertension and other CV risk factors in their diabetic patients. Specific therapeutic regimens for reducing CV events in diabetic patients are presented, including BP lowering, management of lipid abnormalities, antiplatelet therapy, and glucose control.
The various classes of medications employed in the treatment of heart failure are reviewed as well as the clinical trials shaping heart failure therapeutics. Appropriate staging of therapeutics is discussed along with rational polypharmacy. Treatment options for advanced heart failure are concisely presented.
JNC and WHO-ISH management guidelines and results of key clinical trials are reviewed. Recommended approach for treatment is presented together with easy-to-follow treatment algorithms. Drug therapies are extensively discussed, with separate chapters dedicated to each class of antihypertensive medication. Treatment strategies for resistant hypertension are presented.
A practical, concise approach to utilizing the NCEP ATP-III recommendations is presented. The text contains an up-to-date synopsis of the results of major trials of lipid-lowering drugs and a thorough review of pharmacologic treatment options. Separate chapters cover pathophysiology, therapeutic lifestyle changes, and treatment of special populations.
This handbook aims to be an authoritative and thoroughly up-to-date clinical guide to the management of AF, including therapies to restore normal sinus rhythm, maintain sinus rhythm, strategies for rate control and appropriate anticoagulation regimens. Acute care of the AF patient will also be covered in detail. Pivotal clinical trial data will be presented, as will representative case studies.
Low HDL-cholesterol is an independent risk factor for coronary disease and its prevalence is high and increasing. However, HDL is a complex entity that is not well understood. This book reviews what currently is and is not known about HDL and provides an overall understandable framework for the current understanding of HDL. Current knowledge about the clinical impact of HDL on cardiovascular risk is discussed. The data to support current HDL intervention strategies, such as lifestyle changes, statins, niacin, and fibrates, is presented, along with a review of emerging therapeutic agents targeting patients with low HDL, such as CETP inhibitors, PPARs, and apoA-Milano infusion therapy. Coming in Fall/Winter 2011.